Lenalidomide and bb2121 for Multiple Myeloma

"The age requirements for potential participants in this study are between 18-71 years old."

"Lenalidomide and bb2121 have some data backing its safety, but there is not yet any evidence that it is an effective medication. This gives it a Power team safety score of 2."

"This clinical trial, as reported on clinicaltrials.gov, is actively recruiting participants. The original posting was on 1/5/2022, and the most recent update was on 9/22/2022."

"At the moment, this research is being conducted out of 16 different sites. They are situated in New York, Madison, Milwaukee and a selection of other cities. If you're interested in participating it would be ideal to choose a location near to you in order to limit travel."

"Lenalidomide and bb2121 is a immunomodulatory treatment that has shown efficacy in patients with at least two prior systemic chemotherapy regimens, ≥4 prior lines of therapy, amyloidosis."

"The first clinical trial evaluating the lenalidomide and bb2121 combination was conducted in 2004 at Saint Joseph Regional Medical Center-Mishawaka. In total, there have been 346 completed studies investigating this treatment option. As of now, 278 trials are still ongoing with a large number of these based out of New York City."

"The primary objective of this trial is to assess the efficacy of BCMA CAR-T cell therapy over the course of one year. Secondary objectives include measuring disease progression (using the International Myeloma Working Group response categories) and non-relapse mortality rates."

"This study is investigating whether lenalidomide can be an effective treatment for multiple myeloma in patients who have already undergone stem cell transplantation. The trial is looking for 40 participants between the ages of 18 and 71 who meet the following criteria: -Patients must have initiated maintenance therapy with lenalidomide-based regimen within 6 months after the auto HCT and have received at least 3 months of maintenance prior to enrollment.-Patients must have tolerated a minimum dose of lenalidomide 5 mg/day for 21 days of a 28-day cycle for greater than 2 cycles without having to stop due to"

"In order to accurately test the efficacy of the proposed intervention, 40 individuals that meet specific prerequisites are required. These potential participants can be located at different sites, such as Memorial Sloan Kettering Cancer Center in New York or University of Wisconsin Hospitals and Clinics in Madison."